Aggrastat (tirofiban) NDC 25208-901

NDC codes

FDA NDC Directory

Product NDC (as listed)25208-901Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25208-0901Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25208-901-04	25208090104	1 VIAL, GLASS in 1 CARTON (25208-901-04) / 15 mL in 1 VIAL, GLASSMarketed from Oct 15, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Aggrastat
Generic name (nonproprietary): tirofiban
Active ingredients: Tirofiban hydrochloride — 3.75 mg/15mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Medicure International Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020912
Marketing start: Oct 15, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Platelet Aggregation (Physiologic effect)
Identifiers: Product ID 25208-901_d7b2e8c6-afd1-4e94-b780-ed2fc439e3f3SPL ID d7b2e8c6-afd1-4e94-b780-ed2fc439e3f3SPL set ID e850111f-e713-41a2-9c65-21c517cf5511RxCUI 1737466, 1737468, 1737471, 1737472, 1813035, 1813037UNII 6H925F8O5J
Pharmacologic class: Platelet Aggregation Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N425208090104 followed by a unit qualifier and the quantity

Package 25208-0901-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 1, 2025.

Indications (excerpt from the label)

AGGRASTAT® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020912

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020912
Product	Strength	Form · route	Labeler	Product NDC
Aggrastattirofiban	Tirofiban hydrochloride 3.75 mg/15mL	Injection, SolutionIntravenous	Medicure International Inc	25208-001